U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07484022) titled 'Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer' on Feb. 27.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutralize free monomethyl auristatin E (MMAE), a chemotherapy payload released from enfortumab vedotin that is associated with side effects such as peripheral neuropathy.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL...